Company Overview of Pierre Fabre S.A.
Pierre Fabre S.A. is engaged in the design, development, production, and distribution of pharmaceutical products for customers in France and internationally. It offers prescription drugs in onco-hematology, neuropsychiatry, dermatology, women's health, family health, natural health, oral/dental care, and other therapeutic fields; and prescription OTC and drugs for family health, oral care, and natural health. The company also designs and develops solutions for the hygiene, care, and beauty of skin, hair, and scalp; develops and produces active substances of plant, animal, or synthetic origin for the pharmaceutical, cosmetical, and nutraceutical sectors; extracts and produces active substance...
12 Avenue Hoche
Founded in 1951
Key Executives for Pierre Fabre S.A.
Group Chief Executive Officer
Senior Vice-President of Finance & Operations
Chief Executive Officer of Pharmaceuticals Division
Chief Executive Officer of Dermo-Cosmetics Division
Compensation as of Fiscal Year 2014.
Pierre Fabre S.A. Key Developments
Pierre Fabre Opens Subsidiary in Chile
Nov 26 14
Pierre Fabre S.A. has opened a new subsidiary in Chile. According to the source, the subsidiary is the fourth that the French company has opened in Latin America where it has subsidiaries in Brazil, Argentina, and Mexico. The main reason for this investment in Chile was the high-potential landscape in the Chilean market, according to Pierre Fabre's representative in Latin America Stephane Ghozland. This new subsidiary in Chile aims to consolidate Pierre Fabre's presence in the Latin American market and paves the way for the company to strengthen its international operations as well as to boost its oncology business, one of the key development areas for the French pharmaceutical firm. Although the Latin American pharmaceutical market has been attracting international investment due to the fast-growing opportunities in the region as a business alternative to slow growth in Europe and United States, international pharmaceutical companies based in the region should bear in mind some risk such as local production of generics and the internal political regulation to control the prices of medicines.
Pierre Fabre, Aurigene Sign Licence Agreement for Immune Checkpoint Aunp12
Feb 13 14
Pierre Fabre and Aurigene announced the signature of a licensing agreement targeting a novel immune-oncology therapy. In particular Pierre Fabre will receive global rights - except for the Indian market - to the immune checkpoint modulator AUNP-12. The agreement establishes that Pierre Fabre will provide Aurigene with an upfront payment as well as milestones linked to successful development, regulatory progresses, and commercialisation of the candidate product.
Pierre Fabre Plans to Invest USD 23 million in Two French Plants at Gien and Château-Renard
Nov 7 13
Pierre Fabre is planning to implement a restructuring plan in its two French sites located in Gien and Château-Renard worth approximately EUR 17 million (USD 23 million). In particular, by 2018 the Gien plant is expected to resume production of the Château-Renard site which employs 96 people. Château-Renard will then be converted in a packaging site for dermo-cosmetic products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|